Skip to main content
main-content

04-12-2018 | Leukaemia | Video

BCL2 gene mutation confers resistance to venetoclax treatment in CLL patients

Piers Blombery comments on his study results demonstrating that the BCL2 Gly101Val mutation impairs binding of venetoclax to BCL2, leading to an increased risk of chronic lymphocytic leukaemia progression during treatment (2:56).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

image credits